A clinical Study to evaluate the safety and efficacy of Pankajakasthuri Breathe Eazy excel powder
Phase 2
- Conditions
- Health Condition 1: J40-J47- Chronic lower respiratory diseases
- Registration Number
- CTRI/2024/04/065609
- Lead Sponsor
- Pankajakasthuri Herbals India Pvt Ltd P
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Age 18 Years and above
Patients willing to take Breathe
Eazy Excel Powder in a dose of 1 Tea spoon twice daily after food
continuously for a minimum period of 3 months.
Subjects
willing to enroll in study by signing Informed consent.
Subjects presenting with Allergic bronchitis, Allergic rhinitis, COPD,
Sinusitis, Eosinophilia and other Respiratory tract infections.
Exclusion Criteria
1 Patients allergic to the any of the ingredients of Breathe Eazy
Excel Powder.
2. Pregnant and Lactating mother.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Any marked change in safety parameters <br/ ><br>measured during the administration of the <br/ ><br>product. <br/ ><br>• Reporting the effectiveness of this product in <br/ ><br>the management of Allergic bronchitis, Allergic <br/ ><br>rhinitis, COPD, Sinusitis, Eosinophilia and other <br/ ><br>Respiratory tract infections and associated <br/ ><br>complaints.Timepoint: 0th-baseline1st-first time blood investigations <br/ ><br>and 2nd-Blood investigations the end of the <br/ ><br>study.
- Secondary Outcome Measures
Name Time Method Additional therapeutic advantages of the productTimepoint: 0th-baseline1st-first time blood investigations and <br/ ><br>2nd-Blood investigations the end of the study.